Protalix Biotherapeutics Inc (NYSEAMERICAN:PLX) was the target of a large growth in short interest in January. As of January 31st, there was short interest totalling 4,350,894 shares, a growth of 16.6% from the January 12th total of 3,731,432 shares. Currently, 3.1% of the company’s stock are sold short. Based on an average trading volume of 909,146 shares, the days-to-cover ratio is currently 4.8 days.

Protalix Biotherapeutics (NYSEAMERICAN PLX) opened at $0.63 on Monday. The firm has a market cap of $309.48, a price-to-earnings ratio of -0.31 and a beta of 1.02. Protalix Biotherapeutics has a 1-year low of $0.48 and a 1-year high of $1.51.

A hedge fund recently bought a new stake in Protalix Biotherapeutics stock. Opaleye Management Inc. bought a new stake in shares of Protalix Biotherapeutics Inc (NYSEAMERICAN:PLX) during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 1,825,000 shares of the company’s stock, valued at approximately $1,206,000. Opaleye Management Inc. owned approximately 1.27% of Protalix Biotherapeutics at the end of the most recent quarter.

Several equities analysts recently weighed in on PLX shares. Zacks Investment Research upgraded shares of Protalix Biotherapeutics from a “hold” rating to a “buy” rating and set a $1.00 target price on the stock in a report on Tuesday, October 24th. BidaskClub lowered shares of Protalix Biotherapeutics from a “sell” rating to a “strong sell” rating in a report on Saturday, December 2nd. Finally, HC Wainwright restated a “buy” rating and set a $5.00 target price on shares of Protalix Biotherapeutics in a report on Thursday, November 9th.

ILLEGAL ACTIVITY WARNING: This story was first reported by Daily Political and is owned by of Daily Political. If you are accessing this story on another domain, it was illegally stolen and republished in violation of United States & international trademark & copyright laws. The original version of this story can be accessed at

About Protalix Biotherapeutics

Protalix BioTherapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system in Israel and internationally. The company offers taliglucerase alfa for injection, which is an enzyme replacement therapy for the long-term treatment of adult patients with a confirmed diagnosis of type 1 Gaucher disease.

Receive News & Ratings for Protalix Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protalix Biotherapeutics and related companies with's FREE daily email newsletter.